国际皮肤性病学杂志    0  (): 343-345   ISSN: 2096-5540  CN: 32-1880/R   药物基因组学与银屑病治疗药物的关系 涂红琴, 李新宇 中国医学科学院皮肤病研究所, 210042 收稿日期 2007-07-16  修回日期 null  网络版发布日期 null 参考文献  [1] Evans WE,McLeod HL.Pharmacogenomics--drug disposition,drug targets,and side effects.N Engl J Med,2003,348(6):538-549. [2] Meyer UA.Pharmacogenetics and adverse drug reactions Lancet,2000,356(9242):1667-1671. [3] Mehl B,Santell JP.Projecting future drug expenditures.Am J Health Syst Pharm,2000,57(2):129-138. [4] Vasku V,Bienertova Vasku J,Pavkova Goldbergova M,et al.Three retinoid X receptor gene polymorphisms in plaque psoriasis and psoriasis guttata.Dermatology,2007,214(2):118-124. [5] Summers AM,Coupes BM,Brennan MF,et al.VEGF-460 genotype plays an important role in progression to chronic kidney disease stage 5.Nephrol Dial Transplant,2005,20(11):2427-2432. [6] Young HS,Summers AM,Read IR,et al.Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.J Invest Dermatol,2006,126(2):453-459. [7] Mathieu C,van Etten E,Decallonne B,et al.Vitamin D and 1,25-dihvdroxyvitamin D3 as modulators in the immune system.J Steroid Biochem Mol Biol,2004,89-90(1-5):449-452. [8] Saeki H,Asano N,Tsunemi Y,et al.Polymorphisms of vitamin Dreeeptor gene in Japanese patients with psoriasis vulgaris.J Dermatol Sci,2002,30(2):167-171. [9] Halsall JA,Osborme JE,Pringle JH,et al.Vitamin D receptor gene polymorphisms,particularly the novel A-1012G promoter polymorphism,are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis.Pharmacogenet Genomics,2005,15(5):349-355. [10] Warren RB,Griffiths CE.The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.Br J Dermatol,2005,153(5):869-873. [11] Kim RJ,Becker RC.Association between factor V Leiden,prothrombin G20210A,and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system:a meta-analysis of published studies.Am Heart J,2003,146(6):948-957. [12] Kremer JM.Toward a better understanding of methotrexate.Arthritis Rheum,2004,50(5):1370-1382. [13] Hughes LB,Beasley TM,Patel H,et al.Racial or ethnic differences in allele frequencies of single-nueleotide polymorphisms in the methylenetetrahydrofolate reduetase gene and their influence on response to methotrexate in rheumatoid arthritis.Ann Rheum Dis,2006,65(9):1213-1218. [14] van Ede AE,Laan RF,Blom HJ,et al.The C677T mutation in the methylenetetrahydrofolate reductase gene:a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.Arthritis Rheum,2001,144(11):2525-2530. [15] Kumagai K,Hiyama K,Oyama T,et al.Polymorphisms in thethymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.Int J Mol Med,2003,11(5):593-600. [16] Dervieux T,Furst D,Lein DO,et al.Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier,aminoimidazole carboxamide ribonucleotide transformylase,and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.Arthritis Rheum,2004,50(9):2766-2774. [17] Weisman MH,Furst DE,Park GS,et al.Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis.Arthritis Rheum,2006,54(2):607-612. [18] Hu YF,Qiu W,Liu ZQ,et al.Effects of genetic polymorphisms of CYP3A4,CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.Clin Exp Pharmacol Physiol,2006,33(11):1093-1098. [19] Hesselink DA,van Schaik RH,van der Heiden IP,et al.Genetic polymorphisms of the CYP3A4,CYP3A5,and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and taerolimus.Clin Pharmacol Ther,2003,74(3):245-254. 通讯作者: